Catherine Campbell

Senior Director Regulatory Affairs at 4D Molecular Therapeutics LLC - Oakland, CA, US

Catherine Campbell's Colleagues at 4D Molecular Therapeutics LLC
Susan Limb

Vice President, Medical Director, Lung Program

Contact Susan Limb

Ken Glasscock

Senior Director, Scientific Communications

Contact Ken Glasscock

Ken Imamura

Director, Clinical Operations

Contact Ken Imamura

Michael Zanoni

Vice President, Investor Relations & Corporate Affairs

Contact Michael Zanoni

Ariane Maeberry

Administrative Support Assistant

Contact Ariane Maeberry

Keenan Bashour

Senior Director - Upstream Process Development

Contact Keenan Bashour

View All Catherine Campbell's Colleagues
Catherine Campbell's Contact Details
HQ
510-505-2680
Location
San Francisco,California,United States
Company
4D Molecular Therapeutics LLC
Catherine Campbell's Company Details
4D Molecular Therapeutics LLC logo, 4D Molecular Therapeutics LLC contact details

4D Molecular Therapeutics LLC

Oakland, CA, US • 100 - 249 Employees
BioTech/Drugs

We are 4DMT! Our mission is to boldly innovate to unlock the full potential of gene therapy for countless patients. 4DMT is a leader in next-generation AAV gene therapy discovery through its proprietary therapeutic vector evolution platform that empowers us to invent optimized and proprietary AAV vectors, each specifically tailored for the treatment of a rare disease with a high unmet medical need. We strive to become the most impactful company in the gene therapy industry.We are pioneering the development of precision gene therapies based on our proprietary AAV vectors. Our transformative discovery platform, Therapeutic Vector Evolution, enables our "disease first" approach to product discovery, design and development. We use our platform to discover custom and proprietary AAVs designed for specific tissues and diseases, which we believe will allow us to overcome known limitations of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector capsid sequences in our 37 proprietary and diverse AAV vector libraries as of August 1, 2019. We are developing a diverse pipeline in a broad range of therapeutic areas of wholly owned and partnered programs.We seek the best in the industry who identify with our mission and innovative results-driven approach. Our 4 Guiding Principles drive our actions, and they are: Dare to Cure (create big dreams for patients, innovate and take calculated risks to achieve them); Break Boundaries (questioning and moving beyond the status quo); Beyond Yourself (we are patient and team focused); and Prepare & Executive Relentlessly (be proactive and start with the end in mind).

Gene Therapy Adeno-Associated Virus B2B Biotech SaaS Commercial Physical Research Biotechnology Biotech Pharmaceuticals
Details about 4D Molecular Therapeutics LLC
Frequently Asked Questions about Catherine Campbell
Catherine Campbell currently works for 4D Molecular Therapeutics.
Catherine Campbell's role at 4D Molecular Therapeutics is Senior Director Regulatory Affairs.
Catherine Campbell's email address is ***@4dmt.com. To view Catherine Campbell's full email address, please signup to ConnectPlex.
Catherine Campbell works in the Research industry.
Catherine Campbell's colleagues at 4D Molecular Therapeutics LLC are Susan Limb, Kim Maplestone, Ken Glasscock, Ken Imamura, Michael Zanoni, Ariane Maeberry, Keenan Bashour and others.
Catherine Campbell's phone number is 510-505-2680
See more information about Catherine Campbell